Product Description: MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A[1][2][3].
Applications: Cancer-programmed cell death
Formula: C39H65N5O8
Citations: J Control Release. 2018 May 10;277:48-56./Mol Cancer Ther. 2023 Jan 31;MCT-22-0440./Mol Ther Nucleic Acids. 2018 Mar 2;10:227-236./Patent. US20210393733A1./Research Square Preprint. 2023 Dec 4./Research Square Print. 2023 Jan 6th./Target Oncol. 2019 Oct;14(5):577-590./University of Minnesota. 2022 Sep./Oncol Rep. 2020 Dec 9.
References: [1]Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16(9):2562-70./[2]Lee JJ, et al. Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy. Angew Chem Int Ed Engl. 2015 Oct 5;54(41):12020-4./[3]Kim EG, et al. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted CancerTherapeutics./[4]Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006 Jan-Feb;17(1):114-24.
CAS Number: 745017-94-1
Molecular Weight: 731.96
Compound Purity: 99.94
Research Area: Cancer
Solubility: DMSO : 140 mg/mL (ultrasonic)
Target: ADC Cytotoxin;Microtubule/Tubulin
English
Deutsch
